GlassScriptPhysician profile
Keith D Goldstein
NPI 1861462566
$2,054.04
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $1,180 · 2021: $11.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,168.74 | 2019-2020 | |
| Janssen Biotech, INC. | $193.71 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $84.95 | 2019 | |
| Tesaro, INC. | $48.49 | 2019 | |
| Genzyme Corporation | $37.70 | 2019 | |
| Merck Sharp & Dohme LLC | $34.38 | 2019 | |
| Genentech USA, INC. | $34.08 | 2019 | |
| Pfizer INC. | $32.55 | 2019 | |
| Abbvie INC. | $29.91 | 2019 | |
| Janssen Scientific Affairs, LLC | $29.30 | 2019 | |
| Lilly USA, LLC | $28.16 | 2019 | |
| Incyte Corporation | $27.10 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.52 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.72 | 2019 | |
| Celgene Corporation | $23.13 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $22.68 | 2019 | |
| Sun Pharmaceutical Industries INC. | $21.63 | 2019 | |
| Puma Biotechnology, INC. | $20.76 | 2019 | |
| Dova Pharmaceuticals | $19.60 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $18.28 | 2019 | |
| Astellas Pharma US INC | $16.99 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $16.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.12 | 2019 | |
| Exelixis INC. | $14.62 | 2019 | |
| Kyowa Kirin, INC. | $14.55 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.34 | 2019 | |
| Glaxosmithkline, LLC. | $13.39 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.50 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.